Christopher Posner - 03 Aug 2023 Form 4 Insider Report for Cara Therapeutics, Inc. (TVRD)

Reporting relationship: President and CEO, Director
Issuer ticker: TVRD
Reported as of: 03 Aug 2023
Net transaction value: -$13,222
SEC form: 4
Accepted by SEC: 04 Aug 2023, 17:21:53 UTC
Prior SEC filing: 09 May 2023
Next SEC filing: 03 Nov 2023
Source filing: View source filing
Reporting owner signature: /s/Darren DeStefano, Attorney-in-Fact

Key filing fact

Christopher Posner filed Form 4 for Cara Therapeutics, Inc. (TVRD) on 04 Aug 2023.

Key facts

This page summarizes Christopher Posner's Form 4 filing for Cara Therapeutics, Inc. (TVRD).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 04 Aug 2023, 17:21.

Change

Previous filing in this sequence was filed on 09 May 2023.
Current net transaction value: -$13,222.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CARA transaction

Common Stock

Sale

Transaction value: $13,222
Shares: -4,307
Change %: -2.5%
Price: $3.07
Shares after: 168,207
Date: 03 Aug 2023
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on November 2, 2022 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.07 to $3.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.